Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of PT010 and PT003 in Healthy Chinese Adults
NCT03075267Phase 1Completed
- Sponsor
- Pearl Therapeutics
- Start
- Apr 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Breztri Aerosphere in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Pearl Therapeutics. Primary endpoints: Maximum Plasma Concentration at Day 8, Area Under the Plasma Concentration-time Curve From 0-12 Hours at Day 8 and 8 more. Started Apr 2017; status: completed.
02
Drugs
Breztri Aerosphere
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03075267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03075267.